VS18-445-113: A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects with Cystic Fibrosis

Grants and Contracts Details

StatusActive
Effective start/end date7/22/195/27/23

Funding

  • Vertex Pharmaceuticals Inc: $83,455.00